George Church
Showing 1–6 of 6 transcripts.
Race to Save Humanity: Inside $12B Colossal Biosciences & $3.8B Astromech
Ben Lamm, George Church, Molly O'Shea
Colossal is leveraging a de-extinction toolkit and AI-driven "civilization tech" to address an impending 50% global biodiversity loss while raising $400 million in recent capital. Following a breakthrough in generating healthy woolly mice for rapid phenotype testing, the company aims to birth its first extinct species within 12 months by utilizing an 80% efficient cloning arm and open-source technologies. This vertical integration strategy targets ethical textile production and invasive species eradication, operating under strict ethical boundaries that exclude human or primate genome editing.
- Dwarkesh Patel1h 34m
A billion years of evolution in a single afternoon — George Church
At a comprehensive discussion on biotechnology, George Church projected that humanity could achieve aging escape velocity by 2050 through somatic gene therapy and outlined strategies for de-extinction via successive genetic approximations. The event examined critical biosecurity challenges, emphasizing that mandatory oversight and genetic code remapping are essential to counter low-barrier biological threats that voluntary ethics cannot prevent. Furthermore, Church highlighted the convergence of AI and synthetic biology as a catalyst for revolutionary material science and public health interventions, predicting a future where biological precision enables almost perfect health alongside advanced engineering capabilities.
- Goldman Sachs34 min
Colossal Biosciences’ Ben Lamm sees ‘de-extinction’ as vital to fighting climate change
Ben Lamm, Amit Sinha, George Church
Co-founded by CEO Ben Lamb and geneticist George Church, Colossal Biosciences leverages multiplex CRISPR editing to restore extinct species like the woolly mammoth as functional tools for Arctic climate mitigation and biodiversity preservation. The company has secured $225 million in funding to execute a for-profit model generating revenue through carbon credits and ecological services, while simultaneously advancing spin-off technologies in artificial wombs and human medicine. By reintroducing megafauna to the Arctic, Colossal aims to lower ground temperatures and store carbon, with subsequent targets including the Thylacine and Dodo to address global ecological voids.
- The Economist25 min
Gene editing: should you be worried?
James Dale, Isla Mirada, Natalie Kofler, Emmanuelle Charpentier, Jennifer Doudna, Josh Lehrer, Denis Rebrikov, Theresa Blankmeyer-Burke, He Zhongkui, George Church
Recent advancements in CRISPR and gene editing have accelerated scientific capabilities for curing terminal diseases, securing food supplies against extinction events like the banana fungus TR4, and controlling disease vectors, yet these tools introduce significant ethical risks regarding bio-warfare, social inequality, and the potential for designer humans. While regulatory frameworks vary globally between the strict bans in Europe and the more permissive approaches in the US and Japan, controversies persist over transparency in field trials and the morality of germline editing, as highlighted by critiques from bioethicists regarding community consent and the normalization of de-extinction projects. Ultimately, experts warn that without robust, transparent governance to balance rapid innovation with safety, humanity risks undermining public trust while failing to leverage these essential technologies to mitigate climate change and ensure future food security.
- a16z41 min
a16z Podcast | What's in the Water at the George Church Lab?
George Church, Jorge Conde, Hannah
George Church analyzes the 2018 Chinese CRISPR baby case as a pivotal, government-tolerated precedent for germline editing that bypassed ethical moratoriums through a technical strategy of *CCR5* knockout for HIV resistance. He predicts that, similar to the 1978 test-tube baby phenomenon, this "n of 1" success will accelerate adoption and regulation rather than halt research, shifting the field from treatment toward preventative genomic medicine. While Church advocates for robust privacy frameworks like zero-dollar genomes and encryption to overcome security barriers, his broader vision prioritizes environmental applications like mammoth de-extinction over non-therapeutic human editing.
- Milken Institute1h 7m
Precision Medicine, Custom Cures
Margaret Anderson, Mike Polini, Jim Greenwood, George Church, Retta Berry, Chris Austin
Led by former NIH Director Francis Collins and moderated by Margaret Anderson, a diverse panel of scientists, industry leaders, and patient advocates examined the critical gap between rapid advances in precision medicine sequencing and clinical deployment. While the discussion highlighted success stories like the Berry family's transition from a diagnostic odyssey to effective treatment and the rising adoption of gene therapies, it also exposed systemic bottlenecks in rare disease therapeutics, reimbursement models, and data silos that prevent timely translation of genetic discoveries into cures. The group concluded that realizing the full potential of this medical revolution requires structural healthcare reform, robust data-sharing frameworks, and a shift toward participatory medicine where patients actively drive their own health outcomes.